by telrheum | Jun 15, 2024 | Systemic Sclerosis, Autoimmune Diseases, Calcinosis
Background: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases that primarily affect the muscles, causing inflammation. Calcinosis cutis, a condition where calcium deposits form in the skin, often accompanies connective tissue diseases, leading to...
by telrheum | May 27, 2024 | Autoimmune Diseases, Biologic Therapy, IgG4-Related Diseases, JAK Inhibitor
The article “Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients” presents a study conducted at Peking University People’s Hospital. The study aimed to evaluate the effectiveness and safety of tofacitinib, a Janus...
by telrheum | May 27, 2024 | Sjögren’s Syndrome, Systemic Sclerosis
Study Background: This research focuses on finding reliable blood biomarkers to diagnose Interstitial Lung Disease (ILD) in patients with autoimmune diseases, specifically rheumatoid arthritis (RA) and systemic sclerosis (SSc). ILD is a serious complication in these...
by telrheum | May 26, 2024 | Osteoarthritis, Antibody Therapy, Degenerative Arthritis
The study titled “Efficacy, Safety, Pharmacokinetics and Immunogenicity of Repeated Dosing of GSK3858279 in Patients with Knee Osteoarthritis” aimed to evaluate a new treatment for knee osteoarthritis (OA) pain. This treatment, GSK3858279, is a human monoclonal...
by telrheum | May 25, 2024 | Biologic Therapy, Colitis, IL-23 Inhibitors, Interleukin Inhibitors, tumour necrosis factor inhibitors (TNFis)
Background Ulcerative colitis is a chronic inflammatory condition affecting the colon. A recent study investigated the effectiveness of combining two drugs, Simponi, which blocks tumor necrosis factor-alpha, and Tremfya, which inhibits interleukin-23. This combination...